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ABSTRACT
Objectives: Stroke and TIA are recognized complications of acute herpes zoster (HZ). In this study,
we evaluated HZ as a risk factor for cerebrovascular disease (stroke and TIA) and myocardial
infarction (MI) in a UK population cohort.
Methods: A retrospective cohort of 106,601 HZ cases and 213,202 controls matched for
age, sex, and general practice was identified from the THIN (The Health Improvement Network)
general practice database. Cox proportional hazard models were used to examine the risks of
stroke, TIA, and MI in cases and controls, adjusted for vascular risk factors, including body mass
index .30 kg/m2, smoking, cholesterol .6.2 mmol/L, hypertension, diabetes, ischemic heart
disease, atrial fibrillation, intermittent arterial claudication, carotid stenosis, and valvular heart
disease, up to 24 years (median 6.3 years) after HZ occurrence.
Results: Risk factors for vascular disease were significantly increased in cases of HZ compared with
controls. Adjusted hazard ratios (AHRs) for TIA and MI but not stroke were increased in all patients
with HZ (AHR [95%confidence interval]: 1.15 [1.09–1.21] and 1.10 [1.05–1.16], respectively). How-
ever, stroke, TIA, and MI were increased in cases whose HZ occurred when they were younger than
40 years (AHR [95% confidence interval]: 1.74 [1.13–2.66], 2.42 [1.34–4.36], 1.49 [1.04–2.15],
respectively). Subjects younger than 40 years were significantly less likely to be asked about vascular
risk factors than were older patients (p , 0.001).
Conclusion: HZ is an independent risk factor for vascular disease in the UK population, particu-
larly for stroke, TIA, and MI in subjects affected before the age of 40 years. In older subjects, bet-
ter ascertainment of vascular risk factors and earlier intervention may explain the reduction in risk
of stroke after the occurrence of HZ. Neurology® 2014;82:206–212
GLOSSARY
AHR 5 adjusted hazard ratio; BMI 5 body mass index; GP 5 general practitioner; HR 5 hazard ratio; HZ 5 herpes zoster;
HZO 5 herpes zoster ophthalmicus; ICD 5 International Classification of Diseases;MI 5 myocardial infarction; THIN 5 The
Health Improvement Network; VZV 5 varicella-zoster virus.
Herpes zoster (HZ) is caused by varicella-zoster virus (VZV), a ubiquitous pathogen that, after pri-
mary chickenpox in children, persists asymptomatically (latently) in the sensory ganglia, including
the trigeminal ganglion. Reactivation of VZV from latency and translocation, via sensory nerve
endings, to the skin where it replicates is associated with the characteristic HZ rash.1 Both ischemic
and hemorrhagic strokes have been described after HZ affecting the ophthalmic branch of the
trigeminal nerve.2 In these patients, virus spreads transaxonally to cerebral arteries via trigeminal
and other ganglionic afferents.2 At autopsy, viral inclusions, DNA, and antigen present in cerebral
arteries confirms that VZV vasculopathy in these patients is associated with stroke and TIA.2
Similar pathology has also been found in strokes and TIA that follow HZ occurring at non-
ophthalmic sites and even in the absence of rash, raising the possibility that VZV is more widely
implicated in the pathogenesis of cerebrovascular disease.2,3 This possibility is supported by findings
from a Taiwanese population study showing a 30% increase in the incidence of stroke for up to a
year after acute HZ, and a 4.5-fold increase after HZ ophthalmicus (HZO).4,5 We analyzed the risk
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of stroke and TIA after HZ in a large retrospec-
tive UK population-based matched cohort study
followed for up to 24 years (median 6.3 years).
To examine the hypothesis that HZ is a risk
factor for vascular disease in general, we also
measured the risk of myocardial infarction (MI).
METHODS Database sources and study population. The
THIN (The Health Improvement Network) database is a primary
care database that contains anonymous demographic, medical, and
prescription information covering more than 3 million active pa-
tients in the UK. General practitioner (GP) episodes are coded
using READ codes, a standardized hierarchical coding methodol-
ogy similar to the ICD codes, which are used by primary care
physicians (GPs) in the UK to classify medical conditions.6 Patients
in the THIN database are representative of the UK population by
age, sex, medical conditions, and death rates.7 Data were extracted
from patients routinely attending 464 general practices between
2002 and 2010. General practice is the term used in the UK to
denote a group of primary care physicians (GPs).
A retrospective matched cohort study was conducted. Cases
were selected as patients who had experienced HZ. Their index
date was defined as the date of onset of HZ as recorded in the
notes. Patients with recurrent HZ were excluded because this is
a rare form of the disease that is often confused with herpes sim-
plex virus infection.8,9 Patients with HZO, identified using the
relevant code, were included as part of the case cohort.
Controls were identified as patients who had no record of HZ.
To increase the power of the statistical analysis and reduce bias,
2 controls per case were matched according to their age at index
date (6 2 years), sex, and general (primary care) practice. The index
date for controls was defined as the index date of the matched case.
Patients and controls younger than 18 years or who had expe-
rienced a cardiovascular event (stroke, MI, or TIA) before the
index date were excluded. All patients and controls had a minimum
follow-up time of 1 year after the index date. The number of pa-
tients in the THIN database matching the selection criteria resulted
in a power of at least 96% for the statistical analysis.
The THIN codes corresponding to recorded episodes of stroke,
TIA, and MI were identified. This set of codes was used to search
patient and control records for incident stroke, TIA, and MI after
the index date.
Standard protocol approvals, registrations, and patient
consents. This study was reviewed and approved through the
National Research Ethics Service, Scientific Research Committee
reference number 10-013.
Statistical analysis and adjustment for potential sources
of bias. Demographic variables, including age and sex, and risk fac-
tors for vascular disease, including obesity (body mass index [BMI]
.30 kg/m2), smoking status, history of cholesterol .6.2 mmol/L,
hypertension, diabetes, ischemic heart disease, atrial fibrillation,
intermittent arterial claudication, carotid stenosis, and valvular heart
disease, were compared in cases and controls at the index date using
Pearson x2 tests. The proportion of cases and controls for which
BMI, cholesterol level, and smoking status were recorded was also
calculated. Survival analysis was conducted to investigate whether
HZ influenced the time to stroke and, independently, to TIA and
MI. Kaplan-Meier survival curves were generated and the log-rank
test was used to examine differences between the 2 cohorts. Cox
proportional hazard regression models were used to calculate the
hazard ratio (HR) with 95% confidence interval of each of these
outcomes after HZ. The survival models were adjusted for matching
variables, risk factors, and potential confounders for stroke and
MI,10,11 including obesity (BMI .30 kg/m2), smoking status,
history of cholesterol .6.2 mmol/L, hypertension, diabetes,
ischemic heart disease, atrial fibrillation, intermittent arterial
claudication, carotid stenosis, and valvular heart disease. Subgroup
analyses were conducted by age at index date (10-year classes) and
by sex. All statistical analyses were conducted using SAS software
version 9.2 (SAS Institute, Cary, NC).
RESULTS A total of 113,411 cases of HZ were iden-
tified in 3.6 million active patients collected over 23.7
years (median 6.3 years). We excluded 6,696 cases
(5.90%) of recurrent zoster because of the possibility
that they represented misclassified cases of recurrent
herpes simplex.8,9 In addition, 106,601 HZ cases
together with 213,202 controls, 2 for each case,
matched for age, sex, and general practice, were
further evaluated (figure e-1 on the Neurology® Web
site at www.neurology.org). The total person-years
follow-up for cases of HZ was 781,740.
The characteristics of cases and controls are shown
in table 1. The median age of HZ onset was 59.43
years. Risk factors for vascular disease were significantly
more common in cases than in controls (table 2).
Study outcomes. Kaplan-Meier curves of the time to
stroke for cases and controls, up to a maximum of
23.7 years (8,672 days) after acute HZ, are shown in
figure 1. Although the incidence of stroke was higher
in cases than controls, Cox proportional HRs adjusted
for vascular risk factors showed the difference not to
be significant (table 3). The type of stroke (hemorrhage
or infarction) was poorly recorded and there were no
differences between cases and controls in incidence by
stroke pathology (table e-1). Stroke occurring in asso-
ciation with HZO is well described in the literature.2
HZO normally accounts for approximately 16% of cases
of HZ,12 but was recorded in only 1,600 (1.5%) of cases
in the THIN database. Even when cases recorded in
free text and HZ of the head and neck were included,
the number only increased to 2,324 (2.18%). The inci-
dence of stroke, although higher after HZO, did not
differ significantly from that of controls (table 3).
However, the risk of stroke was significantly increased
for subjects whose HZ occurred when they were youn-
ger than 40 years (table 3, figure 2).
The prevalence of TIA and MI in this population is
shown in table 1. After adjustment for confounding
vascular disease risk factors, the time to TIA and MI
was reduced in cases followed for a median of 6.3 years
(2,301 days) (range 1.0–23.7 years) (figure 1). Cox pro-
portional HRs, adjusted for vascular risk factors, showed
a 15% increased risk of TIA and to a lesser extent MI,
associated with HZ (table 3). TIA itself was a risk factor
for stroke, increasing the incidence 7-fold compared
with age-matched controls (14.32% vs 2.07%).
As with stroke, TIA and MI were significantly
increased (2.4- and 1.5-fold, respectively) in those
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whose HZ occurred at ages 18 to 40 years, even when
adjusted for vascular risk factors (figure 2). Most risk
factors for vascular disease were also more common in
subjects whose HZ occurred at age 18 to 40 years, as
compared with matched controls (table e-2). Analysis
of BMI, cholesterol level, and smoking status showed
these to be recorded significantly more frequently in
cases of HZ than in controls (table e-3) but less fre-
quently in subjects aged 18 to 40 years than in older
subjects (table e-4).
DISCUSSION This retrospective cohort study is the
largest to examine HZ as a risk factor for stroke,
TIA, and MI. The study identifies HZ as an indepen-
dent risk factor for TIA and MI occurring up to 24
years after the acute episode in UK adults older than
18 years and for stroke in those aged 18 to 40 years.
The data also confirm that, irrespective of age, condi-
tions that predispose to vascular disease, including
lifestyle factors such as smoking and obesity, which
have not previously been examined, are significantly
more common in subjects with HZ (table 2),
although some of this could be attributable to better
recording of risk factors in patients who present with
HZ (table e-3).
Our study has a number of potential limitations.
Although representative of UK general practices, the
THIN database depends on accurate coding by
GPs.7 Dermatomal HZ is easily diagnosed and coding
has been shown to be accurate in other database stud-
ies.13 To reduce miscoding, we excluded recurrent
HZ, which can be confused with herpes simplex.8,9
The THIN database does not require GPs to specify
location of the HZ, which may explain the 10-fold
lower than expected percentage of HZO cases in this
study compared with previous UK studies (table 1).12
Low levels of HZO recording have also been observed
for another database, the UK General Practice
Research Database.13 The low numbers in this study
limited robust evaluation of HZO as a risk factor for
stroke or other vascular disease.
Recording by GPs of transient neurologic symp-
toms mimicking TIA, for example benign positional
vertigo, which do not predispose to stroke, may have
led to overestimates of the incidence of TIA after HZ
occurrence.14 However, patients with TIA in this
study had a 7-fold higher prevalence of stroke com-
pared with patients who did not experience TIA
(14.32% vs 2.07%). This suggests that records of
TIA in the THIN database, in the main, reflected
typical disease, a finding in line with previous
observations.14
Although the overall prevalence of TIA and MI
was in agreement with published data,14 the preva-
lence of stroke in this population (2.5%) was higher
than for recently reported studies based on other UK
population databases15 (table 1). This could be attrib-
utable to the comparatively longer time span over
Table 2 Comparison of vascular disease risk factors in cases and controls
Risk factor
Cases Controls
p Value of the
x2 testNo. % No. %
Obesity 19,161 18.0 35,597 16.7 ,0.0001
Smoking 37,637 35.3 71,763 33.7 ,0.0001
Cholesterol >6.2 mmol/L 14,962 14.0 26,921 12.6 ,0.0001
Hypertension 26,396 23.8 46,928 22.0 ,0.0001
Diabetes 5,893 5.5 10,372 4.9 ,0.0001
Ischemic heart disease 6,536 6.1 10,274 4.8 ,0.0001
Atrial fibrillation 2,775 2.6 4,683 2.2 ,0.0001
Intermittent arterial claudication 1,042 1.0 1,754 0.8 ,0.0001
Carotid stenosis 74 0.1 99 0.1 0.0084
Valvular heart disease 1,190 1.1 1,977 0.9 ,0.0001
Table 1 Comparison of patients with HZ and matched controls
Characteristic
Patients with HZ
(n 5 106,601)
Matched controls
(n 5 213,202) Total (N 5 319,803)
Mean age at index date, y (SD) 57.9 (17.7) 57.7 (17.7)
Sex, female 63,183 (59.3) 124,620 (59.2)
HZO 1,710 (1.6)
HZ in the head (including HZO) 2,324 (2.1)
Other form of HZ/not specified 104,277 (97.8)
Stroke 5,252 (2.46) 2,727 (2.56) 7,979 (2.49)
Myocardial infarction 4,835 (2.27) 2,762 (2.59) 7,597 (2.38)
TIA 3,904 (1.83) 2,275 (2.13) 6,179 (1.93)
Stroke in patients with HZO (n 5 1,710) 130 (3.80) 68 (3.98) 198 (3.86)
Abbreviations: HZ 5 herpes zoster; HZO 5 HZ ophthalmicus.
Data are numbers (percentage) unless otherwise marked.
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which this analysis was conducted, 24 vs 8 years for
other studies,15 during which time the prevalence of
stroke decreased.15
In the UK, the incidence of stroke has decreased
by more than 30% in the past 10 years.15 This has
been attributed in part to government initiatives
encouraging GPs to screen opportunistically for and
treat vascular risk factors in subjects older than 45
years.15,16 By contrast, in those aged 45 years or youn-
ger, in whom these policies have not been imple-
mented, the incidence of stroke has remained
unchanged over the same time period.15 The possi-
bility that better ascertainment and treatment of vas-
cular risk factors in older subjects may underlie these
differences is supported by our finding that BMI,
smoking status, and cholesterol levels were recorded
less frequently in the notes of those younger than 40
years (tables e-3 and e-4). Better control of vascular
risk factors in older patients presenting with TIA,
which itself increases the risk of stroke, would also
explain why, after HZ, the incidence of TIA but not
stroke was increased in the THIN patient population
as a whole. Together with published data linking
stroke in children with a recent history of chicken-
pox,17–19 these results support a significant role for
VZV, independently of other vascular risk factors,
in the pathogenesis of stroke and cerebrovascular dis-
ease in the UK population, particularly at younger
ages. The results are corroborated by population
cohort studies conducted in Taiwan4 and Denmark,20
both of which identified HZ as a risk factor for
stroke4 or stroke plus TIA.20 The Danish study also
identified the risk of stroke and TIA to be highest in
those whose HZ occurred when they were younger
than 40 years.20 While the risks identified were higher
for the Danish and Taiwanese studies, this may reflect
differences in the study populations and designs. Nei-
ther the Danish nor Taiwanese study controlled for
smoking and BMI, which may have biased results,
while the former reported risks for stroke and TIA
combined. The Danish study was designed to capture
cerebrovascular events associated with acute HZ,
whereas this and the Taiwanese study excluded sub-
jects without a year’s follow-up data. The incidence of
stroke was higher in the Taiwanese study (1.41% at a
year vs 0.3% in this study), but vascular risk factors
were 3 to 5 times more common in the UK. This
could either reflect differences between the popula-
tions, or, after current government recommenda-
tions, more complete ascertainment and treatment
of risk factors in the UK.
How then might the findings of long-term in-
creases in cerebrovascular and MI after HZ be ex-
plained? In the case of HZO, with which strokes
are unequivocally and temporally associated, cranial
artery pathology arises from direct VZV infection
via afferent branches of the ophthalmic branch of
the trigeminal nerve.2,21,22 In such cases, transmural
spread of virus from the adventitia leads to disruption
of the internal elastic lamina, intimal hypertrophy,
and proinflammatory conditions that increase the risk
of stroke.21 However, these mechanisms cannot easily
explain the pathogenesis of stroke or TIA after HZ
Figure 1 Kaplan-Meier curves for the risk of stroke, TIA, and MI over the study
follow-up period
The time to stroke (A) after the index date does not differ significantly for cases of herpes
zoster and matched controls, but is significantly shorter for TIA (B) and myocardial infarction
(MI) (C) in cases compared with controls.
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located outside the head and neck or even of MI after
HZ. Vascular events occurring within days of HZ
could be due to the associated inflammatory response,
as has been described for stroke and MI after acute
respiratory or urinary tract infections.23 However, this
cannot explain the increased risk persisting for
months and years after acute HZ. The discovery in
recent years that VZV DNA can be detected in oral
fluid and blood both in subjects whose rash is outside
the head and neck and even in the absence of rash
provides a possible explanation.24227 In theory,
asymptomatic reactivation of VZV from cranial
nerves, detectable as virus in saliva, could also lead
to infection of cranial arteries, stroke, and TIA,
including in the absence of HZ rash and when the
rash occurs in noncranial dermatomes.26 This
hypothesis is supported by findings from simian var-
icella virus infection of macaques, a model for VZV.28
In this model, asymptomatic reactivation of simian
varicella virus from trigeminal ganglia with the poten-
tial to spread to cranial arteries has been detected in
macaques with thoracic zoster.29 In humans, VZV
antigen has been demonstrated in arterial adventitial
tissue, together with intimal hypertrophy, within skip
lesions present in the cerebral arteries of diabetics
without a history of HZ.30 Notwithstanding the lack
of history in these cases, diabetics are known to be at
increased risk of HZ.31 Furthermore, asymptomatic
shedding of virus in saliva is significantly more com-
mon in those with a history of HZ.26 Taken together,
the possibility remains that certain individuals who
are predisposed to HZ are also more likely to shed
virus asymptomatically, and that both represent a risk
for cerebrovascular disease. At the same time, asymp-
tomatic reactivation of VZV from latency in thoracic
sympathetic ganglia32 with transaxonal spread via
adrenergic nerves to systemic arteries could explain
the ongoing risk of MI long after an episode of HZ.
Although accounting for 15% to 20% of all cases,33
the incidence of HZ is comparatively low for those
younger than 40 years.12 This together with the fact
that those whose HZ occurs at ages 18 to 40 years are
less likely to have predisposing immunosuppressive
conditions33 suggest a predisposition in this group
to VZV reactivation and a lifetime increased risk of
vascular disease. VZV DNA has also been detected in
blood for months after the resolution of HZ34 and in
asymptomatic children receiving intensive care.27 If
circulating virus is able to infect arterial tissue, partic-
ularly when damaged by preexisting risk factors, this
too could contribute to prolonged inflammation with
increased vascular insult. In this scenario, control of
risk factors that predispose to arterial damage might
mitigate the risk from HZ, which in turn might
explain our findings that strokes are not more com-
mon in UK citizens older than 40 years. Taken
together, the finding that virus reacts asymptomati-
cally from cranial nerves resulting in prolonged oral
shedding,24,25,34 particularly in subjects with a history
of HZ,26 and circulation in the blood,27,34 provides a
set of testable hypotheses to explain the increased risk
of TIA, MI, and in some cases stoke, persisting for
years after an episode of HZ particularly in the pres-
ence of risk factors for vascular disease. The possibility
that VZV directly exacerbates preexisting arterial
damage would also explain why effective management
of risk factors has reduced the incidence of stroke after
HZ occurrence in the older UK subjects.
Overall, these data add to the growing body of evi-
dence linking VZV, a ubiquitous pathogen that es-
tablishes persistent infection in more than 95% of
individuals, to vascular disease. Immunization with
the licensed zoster vaccine has been shown to signif-
icantly reduce the incidence of HZ as well as
Table 3 Hazard ratios (95% CI) for stroke, TIA, and MI after herpes zoster occurrence
Vascular eventa Cases (n 5 106,601), n (%) Controls (n 5 213,202), n (%)
Hazard ratio (95% CI)
Unadjusted Adjustedb
Stroke 2,727 (2.49) 5,252 (2.46) 1.04 (0.99–1.09) 1.02 (0.98–1.07)
MI 2,762 (2.59) 4,835 (2.38) 1.15 (1.09–1.20) 1.10 (1.05–1.16)c
TIA 2,275 (2.13) 3,901 (1.83) 1.17 (1.11–1.23) 1.15 (1.09–1.21)c
Stroke in patients with HZO (n 5 2,324) 68 (3.98) 130 (3.90) 1.06 (0.79–1.42) 1.03 (0.77–1.39)
Stroke in subjects 18–40 y (n 5 19,301) 40 (0.21) 45 (0.12) 1.79 (1.17–2.73) 1.74 (1.13–2.66)c
MI in subjects 18–40 y (n 5 19,301) 51 (0.26) 67 (0.17) 1.53 (1.06–2.20) 1.49 (1.04–2.15)c
TIA in subjects 18–40 y (n 5 19,301) 25 (0.13) 20 (0.05) 2.51 (1.39–4.52) 2.42 (1.34–4.36)c
Abbreviations: CI 5 confidence interval; HZO 5 herpes zoster ophthalmicus; MI 5 myocardial infarction.
a Period of follow-up 1 to 23.7 years.
bHazard ratios were adjusted for sex, age, obesity (body mass index .30 kg/m2), smoking status, history of cholesterol .6.2 mmol/L, hypertension,
diabetes, ischemic heart disease, atrial fibrillation, intermittent arterial claudication, carotid stenosis, and valvular heart disease.
cp , 0.05.
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significantly decrease the severity of neuropathic com-
plications.35 Population studies are now needed to
evaluate whether immunization to prevent HZ could
also reduce the incidence of vascular events including
stroke, TIA, and MI. More research is needed to
understand the pathogenesis of increased HZ in pa-
tients with risk factors for vascular disease and to
determine the impact of treatment on risk. Impor-
tantly, the role, if any, of asymptomatic VZV reacti-
vation in the pathogenesis of vascular disease and how
this might be affected by zoster immunization needs
further clarification. In the meantime, the vaccine
could now be offered to adults with risk factors for
vascular disease, irrespective of age, to reduce the asso-
ciated risk of HZ.4,31 At the same time, screening for
vascular risk factors in patients presenting with HZ,
especially younger patients in whom intervention
may have the most impact, should now be encour-
aged. Ultimately, high-coverage childhood varicella
vaccination to reduce latency with wild-type virus is
altogether desirable.
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CORRECTION
Herpes zoster as a risk factor for stroke and TIA: A retrospective cohort study in the UK
The original version of the article “Herpes zoster as a risk factor for stroke and TIA: A retrospective cohort study in the
UK” by J. Breuer et al. (Neurology® 2014;82:206–212), which was published online ahead of print on January 2,
2014, had errors in the abstract, tables 1 and 3, and related text. An Expression of Concern was published by the
Editors (EDITORIAL EXPRESSION OF CONCERN: Herpes zoster as a risk factor for stroke and TIA: A retro-
spective cohort study in the UK, online ahead of print February 5, 2014) and the authors have since corrected the
errors. The abstract should have indicated that the risk of stroke, TIA, and MI for those under 40 was 1.74 (1.13–
2.66), 2.42 (1.34–4.36), and 1.49 (1.04–2.15), respectively. In tables 1 and 3, there were errors in the counts and
percentages for stroke, MI, TIA, and stroke in HZO patients, as well as an error in the number of cases of stroke in
HZO patients. Under “Study Outcomes,” the fifth sentence should read: “HZO normally accounts for approximately
16% of cases of HZ,12 but was recorded in only 1,710 (1.6%) of cases in the THIN database.” The corrected tables are
published below, and the journal will publish a corrected complete version of the article in an upcoming issue. The
authors regret the errors.
Table 3 Hazard ratios (95% CI) for stroke, TIA, and MI after herpes zoster occurrence
Vascular eventa
Cases
(n 5 106,601),
n (%)
Controls
(n 5 213,202),
n (%)
Hazard ratio (95% CI)
Unadjusted Adjustedb
Stroke 2,727 (2.56) 5,252 (2.46) 1.04 (0.99-1.09) 1.02 (0.98-1.07)
MI 2,762 (2.59) 4,835 (2.27) 1.15 (1.09-1.20) 1.10 (1.05-1.16)c
TIA 2,275 (2.13) 3,904 (1.83) 1.17 (1.11-1.23) 1.15 (1.09-1.21)c
Stroke in patients with HZO
(cases 5 1,710; controls 5 3,240)
68 (3.98) 130 (3.80) 1.06 (0.79-1.42) 1.03 (0.77-1.39)
Stroke in subjects 18-40 y
(cases 5 19,301;
controls 5 38,602)
40 (0.21) 45 (0.12) 1.79 (1.17-2.73) 1.74 (1.13-2.66)c
MI in subjects 18-40 y (cases
19,301; controls 5 38,602)
51 (0.26) 67 (0.17) 1.53 (1.06-2.20) 1.49 (1.04-2.15)c
TIA in subjects 18-40 y (cases
19,301; controls 5 38,602)
25 (0.13) 20 (0.05) 2.51 (1.39-4.52) 2.42 (1.34-4.36)c
Abbreviations: CI 5 confidence interval; HZO 5 herpes zoster ophthalmicus; MI 5 myocardial infarction.
a Period of follow-up 1 to 23.7 years.
b Hazard ratios were adjusted for sex, age, obesity (body mass index .30 kg/m2), smoking status, history of
cholesterol .6.2 mmol/L, hypertension, diabetes, ischemic heart disease, atrial fibrillation, intermittent arterial
claudication, carotid stenosis, and valvular heart disease.
c p , 0.05.
Table 1 Comparison of patients with herpes zoster and matched controls
Patients with HZ Matched controls Total
Characteristic (n 5 106,601) (n 5 213,202) (N 5 319,803)
Age at index date 57.9 (17.7) 57.7 (17.7)
Sex, female 63,183 (59.3) 124,620 (59.2)
HZO 1,710 (1.6)
HZ in the head (including HZO) 2,324 (2.1)
Other form of HZ/not specified 104,277 (97.8)
Stroke 2,727 (2.56) 5,252 (2.46) 7,979 (2.49)
Myocardial infarction 2,762 (2.59) 4,835 (2.27) 7,597 (2.38)
TIA 2,275 (2.13) 3,904 (1.83) 6,179 (1.93)
Stroke in patients with HZO (cases 5 1,710;
controls 5 3,420; total 5 5,130)
68 (3.98) 130 (3.80) 198 (3.86)
Abbreviations: HZ 5 herpes zoster; HZO 5 HZ ophthalmicus. Data are n (%) unless otherwise specified.
Author disclosures are available upon request (journal@neurology.org).
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ABSTRACT
Objectives: Stroke and TIA are recognized complications of acute herpes zoster (HZ). Herein, we
evaluate HZ as a risk factor for cerebrovascular disease (stroke and TIA) and myocardial infarction
(MI) in a UK population cohort.
Methods: A retrospective cohort of 106,601 HZ cases and 213,202 controls, matched for age,
sex, and general practice, was identified from the THIN (The Health Improvement Network)
general practice database. Cox proportional hazard models were used to examine the risks of
stroke, TIA, and MI in cases and controls, adjusted for vascular risk factors, including body mass
index .30 kg/m2, smoking, cholesterol .6.2 mmol/L, hypertension, diabetes, ischemic heart
disease, atrial fibrillation, intermittent arterial claudication, carotid stenosis, and valvular heart
disease, over 24 (median 6.3) years after HZ infection.
Results: Risk factors for vascular disease were significantly increased in cases of HZ compared
with controls. Adjusted hazard ratios for TIA and MI but not stroke were increased in all patients
with HZ (adjusted hazard ratios [95% confidence intervals]: 1.15 [1.09–1.21] and 1.10 [1.05–
1.16], respectively). However, stroke, TIA, and MI were increased in cases whose HZ occurred
when they were younger than 40 years (adjusted hazard ratios [95% confidence intervals]: 1.74
[1.13–2.66], 2.42 [1.34–4.36], and 1.49 [1.04–2.15], respectively). Subjects younger than
40 years were significantly less likely to be asked about vascular risk factors compared with
older patients (p , 0.001).
Conclusion: HZ is an independent risk factor for vascular disease in the UK population, particu-
larly for stroke, TIA, and MI in subjects affected before the age of 40 years. In older subjects, bet-
ter ascertainment of vascular risk factors and earlier intervention may explain the reduction in risk
of stroke after HZ infection. Neurology® 2014;83:e27–e33
GLOSSARY
BMI 5 body mass index; GP 5 general practitioner; HZ 5 herpes zoster; HZO 5 herpes zoster ophthalmicus; ICD 5 Inter-
national Classification of Diseases; MI 5 myocardial infarction; THIN 5 The Health Improvement Network; VZV 5 varicella-
zoster virus.
Herpes zoster (HZ) is caused by varicella-zoster virus (VZV), a ubiquitous pathogen, which,
after primary chickenpox in children, persists asymptomatically (latently) in the sensory ganglia,
including the trigeminal ganglion. Reactivation of VZV from latency and translocation, via sen-
sory nerve endings, to the skin where it replicates is associated with the characteristic HZ rash.1
Both ischemic and hemorrhagic strokes have been described after HZ affecting the ophthalmic
branch of the trigeminal nerve.2 In these patients, virus spreads transaxonally to cerebral arteries,
via trigeminal and other ganglionic afferents.2 At autopsy, viral inclusions, DNA, and antigen
present in cerebral arteries confirms that VZV vasculopathy in these patients is associated with
stroke and TIA.2 Similar pathology has also been found in strokes and TIA, which follow HZ
occurring at nonophthalmic sites and even in the absence of rash, raising the possibility that
VZV is more widely implicated in the pathogenesis of cerebrovascular disease.2,3 This possibility
is supported by findings from a Taiwanese population study showing a 30% increase in the
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incidence of stroke for up to a year after acute
HZ, and a 4.5-fold increase after HZ ophthal-
micus (HZO).4,5 Herein, we analyze the risk of
stroke and TIA after HZ in a large retrospective
UK population-based matched cohort study
followed for up to 24 years (median 6.3 years).
To examine the hypothesis that HZ is a risk
factor for vascular disease in general, we also
measure the risk of myocardial infarction (MI).
METHODS Database sources and study population. The
THIN (The Health Improvement Network) database is a pri-
mary care database that contains anonymous demographic, med-
ical, and prescription information covering more than 3 million
active patients in the United Kingdom. General practitioner
(GP) episodes are coded using READ codes, a standardized hier-
archical coding methodology similar to the ICD codes, which are
used by primary care physicians (GPs) in the UK to classify med-
ical conditions.6 Patients in the THIN database are representative
of the UK population by age, sex, medical conditions, and death
rates.7 Data were extracted from patients routinely attending 464
general practices between 2002 and 2010. General practice is the
term used in the United Kingdom to denote a group of primary
care physicians (GPs).
A retrospective matched cohort study was conducted. Cases
were selected as patients who had experienced HZ. Their index
date was defined as the date of onset of HZ as recorded in the
notes. Patients with recurrent HZ were excluded because this is
a rare form of the disease that is often confused with herpes sim-
plex virus infection.8,9 Patients with HZO, identified using the
relevant code, were included as part of the case cohort.
Controls were identified as patients who had no record of
HZ. To increase the power of the statistical analysis and reduce
bias, 2 controls per case were matched according to their age at
index date (62 years), sex, and general (primary care) practice.
The index date for controls was defined as the index date of the
matched case.
Patients and controls younger than 18 or who had experi-
enced a cardiovascular event (stroke, MI, or TIA) before the index
date were excluded. All patients and controls had a minimum
follow-up time of 1 year after the index date. The number of
patients in the THIN database matching the selection criteria re-
sulted in a power of at least 96% for the statistical analysis.
The THIN codes corresponding to recorded episodes of
stroke, TIA, and MI were identified. This set of codes was used
to search patient and control records for incident stroke, TIA,
and MI after the index date.
Standard protocol approvals, registrations, and patient
consents. This study was reviewed and approved through the
National Research Ethics Service, Scientific Research Committee
reference number 10-013.
Statistical analysis and adjustment for potential sources
of bias. Demographic variables, including age and sex, and
risk factors for vascular disease including obesity (body
mass index [BMI] .30 kg/m2), smoking status, history of
cholesterol .6.2 mmol/L, hypertension, diabetes, ischemic
heart disease, atrial fibrillation, intermittent arterial claudica-
tion, carotid stenosis, and valvular heart disease, were compared
in cases and controls at the index date using Pearson x2 tests.
The proportion of cases and controls for which BMI, choles-
terol level, and smoking status were recorded was also calcu-
lated. Survival analysis was conducted to investigate whether
HZ influenced the time to stroke and, independently, to TIA
and MI. Kaplan-Meier survival curves were generated and
the log-rank test was used to examine differences between the 2
cohorts. Cox proportional hazard regression models were used to
calculate the hazard ratio with 95% confidence interval of each of
these outcomes after HZ. The survival models were adjusted for
matching variables, risk factors, and potential confounders for
stroke and MI,10,11 including obesity (BMI .30 kg/m2), smoking
status, history of cholesterol.6.2 mmol/L, hypertension, diabetes,
ischemic heart disease, atrial fibrillation, intermittent arterial
claudication, carotid stenosis, and valvular heart disease.
Subgroup analyses were conducted by age at index date (10-year
classes) and by sex. All statistical analyses were conducted using SAS
version 9.2 (SAS Institute, Cary, NC).
RESULTS A total of 113,411 cases of HZ were iden-
tified in 3.6 million active patients collected over 23.7
years (median 6.3 years). We excluded 6,696 cases
(5.90%) of recurrent zoster because of the possibility
that they represented misclassified cases of recurrent
herpes simplex.8,9 We further evaluated 106,601
HZ cases together with 213,202 controls, 2 for each
case, matched for age, sex, and general practice (figure
e-1 on the Neurology® Web site at Neurology.org).
The total person-years follow-up for cases of HZ was
781,740.
The characteristics of cases and controls are shown
in table 1. The median age of HZ onset was 59.43
years. Risk factors for vascular disease were significantly
more common in cases than in controls (table 2).
Study outcomes. Kaplan-Meier curves of the time to
stroke for cases and controls, up to a maximum of
23.7 years (8,672 days) after acute HZ, are shown
in figure 1. Although the incidence of stroke was
higher in cases than controls, Cox proportional haz-
ard ratios, adjusted for vascular risk factors, showed
the difference not to be significant (table 3). The type
of stroke (hemorrhage or infarction) was poorly
Table 1 Comparison of patients with HZ and matched controls
Characteristic
Patients with HZ
(n 5 106,601)
Matched controls
(n 5 213,202)
Total
(N 5 319,803)
Age at index date 57.9 (17.7) 57.7 (17.7)
Sex, female 63,183 (59.3) 124,620 (59.2)
HZO 1,710 (1.6)
HZ in the head (including HZO) 2,324 (2.1)
Other form of HZ/not specified 104,277 (97.8)
Stroke 2,727 (2.56) 5,252 (2.46) 7,979 (2.49)
Myocardial infarction 2,762 (2.59) 4,835 (2.27) 7,597 (2.38)
TIA 2,275 (2.13) 3,904 (1.83) 6,179 (1.93)
Stroke in patients with HZO
(cases 5 1,710; controls 5
3,420; total 5 5,130)
68 (3.98) 130 (3.80) 198 (3.86)
Abbreviations: HZ 5 herpes zoster; HZO 5 HZ ophthalmicus.
Data are n (%) unless otherwise specified.
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recorded, and there were no differences between cases
and controls in incidence by stroke pathology (table
e-1). Stroke occurring in association with HZO is
well described in the literature.2 HZO normally ac-
counts for approximately 16% of cases of HZ,12 but
was recorded in only 1,710 (1.6%) of cases in the
THIN database. Even when cases recorded in free
text and HZ of the head and neck were included,
the number only increased to 2,324 (2.18%). The
incidence of stroke, although higher after HZO, did
not differ significantly from that of controls (table 3).
However, the risk of stroke was significantly increased
for subjects whose HZ occurred before the age of 40
years (table 3, figure 2).
The prevalence of TIA and MI in this population is
shown in table 1. After adjustment for confounding
vascular disease risk factors, the time to TIA and MI
was reduced in cases followed for a median of 6.3 years
(2,301 days) (range: 1.0–23.7 years) (figure 1). Cox
proportional hazard ratios, adjusted for vascular risk
factors, showed a 15% increased risk of TIA and to a
lesser extent MI, associated with HZ (table 3). TIA
itself was a risk factor for stroke, increasing the inci-
dence 7-fold compared with age-matched controls
(14.32% vs 2.07%).
As with stroke, TIA and MI were significantly
increased (2.4- and 1.5-fold, respectively) in those
whose HZ occurred between the ages of 18 and
40 years, even when adjusted for vascular risk factors
(figure 2). Most risk factors for vascular disease were
also more common in subjects whose HZ occurred
between the ages 18 and 40 years, compared with
matched controls (table e-2). Analysis of BMI, cho-
lesterol level, and smoking status showed them to be
recorded significantly more frequently in cases of HZ
as compared with controls (table e-3), but less fre-
quently in subjects aged 18 to 40 years than in older
subjects (table e-4).
DISCUSSION This retrospective cohort study is the
largest to examine HZ as a risk factor for stroke,
TIA, and MI. The study identifies HZ as an indepen-
dent risk factor for TIA and MI occurring up to 24
years after the acute episode in UK adults older than
18 years and for stroke in those aged 18 to 40 years.
The data also confirm that, irrespective of age, condi-
tions that predispose to vascular disease, including
lifestyle factors such as smoking and obesity, which
have not previously been examined, are significantly
more common in subjects with HZ (table 2),
although some of this could be attributable to better
recording of risk factors in patients who present with
HZ (table e-3).
Our study has a number of potential limitations.
Although representative of UK general practices, the
THIN database depends on accurate coding by
GPs.7 Dermatomal HZ is easily diagnosed and coding
has been shown to be accurate in other database stud-
ies.13 To reduce miscoding, we excluded recurrent
HZ, which can be confused with herpes simplex.8,9
The THIN database does not require GPs to specify
location of the HZ, which may explain the 10-fold
lower than expected percentage of HZO cases in this
study compared with previous UK studies (table 1).12
Low levels of HZO recording has also been observed
for another UK general practice database, the
GPRD.13 The low numbers in this study limited
robust evaluation of HZO as a risk factor for stroke
or other vascular disease.
Recording by GPs of transient neurologic symp-
toms mimicking TIA, for example benign positional
vertigo, which do not predispose to stroke, may have
led to overestimates of the incidence of TIA after
HZ.14 However, patients with TIA in this study
had a 7-fold higher prevalence of stroke as compared
with patients who did not experience TIA (14.32% vs
2.07%). This suggests that records of TIA in the
Table 2 Comparison of vascular disease risk factors in cases and controls
Risk factor
Cases Controls
p Value of the x2 testNo. % No. %
Obesity 19,161 18.0 35,597 16.7 ,0.0001
Smoking 37,637 35.3 71,763 33.7 ,0.0001
Cholesterol >6.2 mmol/L 14,962 14.0 26,921 12.6 ,0.0001
Hypertension 26,396 23.8 46,928 22.0 ,0.0001
Diabetes 5,893 5.5 10,372 4.9 ,0.0001
Ischemic heart disease 6,536 6.1 10,274 4.8 ,0.0001
Atrial fibrillation 2,775 2.6 4,683 2.2 ,0.0001
Intermittent arterial claudication 1,042 1.0 1,754 0.8 ,0.0001
Carotid stenosis 74 0.1 99 0.1 0.0084
Valvular heart disease 1,190 1.1 1,977 0.9 ,0.0001
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THIN database, in the main, reflected typical disease,
a finding in line with previous observations.14
Although the overall prevalence of TIA and MI
was in line with published data,14 the prevalence of
stroke in this population (2.5%) was higher than for
recently reported studies based on other UK popula-
tion databases15 (table 1). This could be attributable
to the comparatively longer time span over which this
analysis was conducted, 24 vs 8 years for other stud-
ies,15 during which time the prevalence of stroke
decreased.15
In the United Kingdom, the incidence of stroke
has decreased by more than 30% in the past 10
years.15 This has been attributed, in part, to govern-
ment initiatives encouraging GPs to screen opportu-
nistically for, and treat vascular risk factors in subjects
older than 45 years.15,16 By contrast, in those aged 45
years or younger, in whom these policies have not
been implemented, the incidence of stroke has re-
mained unchanged over the same time period.15
The possibility that better ascertainment and treat-
ment of vascular risk factors in older subjects may
underlie these differences is supported by our finding
that BMI, smoking status, and cholesterol levels were
recorded less frequently in the notes of those younger
than 40 years (tables e-3 and e-4). Better control of
vascular risk factors in older patients presenting with
TIA, which itself increases the risk of stroke, would
also explain why, after HZ, the incidence of TIA but
not stroke was increased in the THIN patient popu-
lation as a whole. Together with published data link-
ing stroke in children with recent history of
chickenpox,17–19 these results support a significant
role for VZV, independently of other vascular risk
factors, in the pathogenesis of stroke and cerebrovas-
cular disease in the UK population, particularly at
younger ages. The results are corroborated by popu-
lation cohort studies conducted in Taiwan4 and Den-
mark,20 both of which identified HZ as a risk factor
for stroke4 or stroke plus TIA.20 The Danish study
also identified the risk of stroke and TIA to be highest
in those whose HZ occurred under the age of 40
years.20 While the risks identified were higher for
the Danish and Taiwanese studies, this may reflect
differences in the study populations and designs. Nei-
ther the Danish nor Taiwanese studies controlled for
smoking and BMI, which may have biased results,
while the former reported risks for stroke and TIA
combined. The Danish study was designed to capture
cerebrovascular events associated with acute HZ,
whereas this and the Taiwanese study excluded subjects
without a year’s follow-up data. The incidence of stroke
was higher in the Taiwanese study (1.41% at a year vs
0.3% in this study) but vascular risk factors were 3 to
5 times more common in the United Kingdom. This
could either reflect differences between the populations,
or, following current government recommendations,
more complete ascertainment and treatment of risk
factors in the United Kingdom.
How then might the findings of long-term
increases in cerebrovascular disease and MI after
Figure 1 Kaplan-Meier curves for the risk of stroke, TIA, and MI over the study
follow-up period
Time to stroke (A) after index date does not differ significantly for cases of herpes zoster and
matched controls, but is significantly shorter for TIA (B) and MI (C) in cases compared with
controls. MI 5 myocardial infarction.
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HZ be explained? In the case of HZO, with which
strokes are unequivocally and temporally associated,
cranial artery pathology arises from direct VZV infec-
tion via afferent branches of the ophthalmic branch of
the trigeminal nerve.2,21,22 In such cases, transmural
spread of virus from the adventitia leads to disruption
of the internal elastic lamina, intimal hypertrophy,
and proinflammatory conditions, which increase the
risk of stroke.21 However, these mechanisms cannot
easily explain the pathogenesis of stroke, or TIA after
HZ located outside the head and neck or even of MI
after HZ. Vascular events occurring within days of
HZ could be due to the associated inflammatory
response, as has been described for stroke and MI
after acute respiratory or urinary tract infections.23
However, this cannot explain the elevated risk persist-
ing for months and years after acute HZ. The discov-
ery in recent years that VZV DNA can be detected in
oral fluid and blood both in subjects whose rash is
outside the head and neck and even in the absence of
rash provides a possible explanation.24–27 In theory,
asymptomatic reactivation of VZV from cranial
nerves, detectable as virus in saliva, could also lead
to infection of cranial arteries, stroke, and TIA,
including in the absence of HZ rash, and when the
rash occurs in noncranial dermatomes.26 This
hypothesis is supported by findings from simian var-
icella virus infection of macaques, a model for VZV.28
In this model, asymptomatic reactivation of simian
varicella virus from trigeminal ganglia with the poten-
tial for spread to cranial arteries has been detected in
macaques with thoracic zoster.29 In humans, VZV
antigen has been demonstrated in arterial adventitial
tissue, together with intimal hypertrophy, within skip
lesions present in the cerebral arteries of diabetics with-
out a history of HZ.30 Notwithstanding the lack of
history in these cases, diabetics are known to be at
increased risk of HZ.31 Furthermore, asymptomatic
shedding of virus in saliva is significantly more common
in those with a history of HZ.26 Taken together, the
possibility remains that certain individuals who are pre-
disposed to HZ are also more likely to shed virus
asymptomatically, and that both represent a risk for
cerebrovascular disease. At the same time, asymptom-
atic reactivation of VZV from latency in thoracic sym-
pathetic ganglia32 with transaxonal spread via adrenergic
nerves to systemic arteries could explain the ongoing
risk of MI long after an episode of HZ. Although
accounting for 15% to 20% of all cases,33 the incidence
of HZ is comparatively low under the age of 40 years.12
This together with the fact that those whose HZ occurs
at ages 18 to 40 years are less likely to have predisposing
immunosuppressive conditions33 suggests a constitutive
predisposition in this group to VZV reactivation and a
lifetime’s increased risk of vascular disease. VZV DNA
has also been detected in blood for months after the
resolution of HZ34 and in asymptomatic children
receiving intensive care.27 If circulating virus is able to
infect arterial tissue, particularly when damaged by pre-
existing risk factors, this too could contribute to pro-
longed inflammation with increased vascular insult. In
this scenario, control of risk factors that predispose to
arterial damage might mitigate the risk fromHZ, which
in turn might explain our findings that strokes are not
more common in UK citizens older than 40 years.
Taken together, the finding that virus reacts asymptom-
atically from cranial nerves, resulting in prolonged oral
shedding24,25,34 particularly in subjects with a history of
Table 3 Hazard ratios (95% CI) for stroke, TIA, and MI after herpes zoster occurrence
Vascular eventa
Cases
(n 5 106,601), n (%)
Controls
(n 5 213,202), n (%)
Hazard ratio (95% CI)
Unadjusted Adjustedb
Stroke 2,727 (2.56) 5,252 (2.46) 1.04 (0.99–1.09) 1.02 (0.98–1.07)
MI 2,762 (2.59) 4,835 (2.27) 1.15 (1.09–1.20) 1.10 (1.05–1.16)c
TIA 2,275 (2.13) 3,904 (1.83) 1.17 (1.11–1.23) 1.15 (1.09–1.21)c
Stroke in patients with HZO
(cases 5 1,710; controls 5 3,240)
68 (3.98) 130 (3.80) 1.06 (0.79–1.42) 1.03 (0.77–1.39)
Stroke in subjects 18–40 y
(cases 5 19,301; controls 5 38,602)
40 (0.21) 45 (0.12) 1.79 (1.17–2.73) 1.74 (1.13–2.66)c
MI in subjects 18–40 y
(cases 5 19,301; controls 5 38,602)
51 (0.26) 67 (0.17) 1.53 (1.06–2.20) 1.49 (1.04–2.15)c
TIA in subjects 18–40 y
(cases 5 19,301; controls 5 38,602)
25 (0.13) 20 (0.05) 2.51 (1.39–4.52) 2.42 (1.34–4.36)c
Abbreviations: CI 5 confidence interval; HZO 5 herpes zoster ophthalmicus; MI 5 myocardial infarction.
a Period of follow-up 1 to 23.7 years.
bHazard ratios were adjusted for sex, age, obesity (body mass index .30 kg/m2), smoking status, history of cholesterol
.6.2 mmol/L, hypertension, diabetes, ischemic heart disease, atrial fibrillation, intermittent arterial claudication, carotid
stenosis, and valvular heart disease.
cp , 0.05.
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HZ,26 and circulation in the blood,27,34 provides a set of
testable hypotheses to explain the increased risk of TIA,
MI, and in some cases stroke, persisting for years after
an episode of HZ, particularly in the presence of risk
factors for vascular disease. The possibility that VZV
directly exacerbates preexisting arterial damage would
also explain why effective management of risk factors
has reduced the incidence of stroke after HZ in the
older UK subjects.
Overall, these data add to the growing body of evi-
dence linking VZV, a ubiquitous pathogen that estab-
lishes persistent infection in more than 95% of
individuals, to vascular disease. Immunization with
the licensed zoster vaccine has been shown to signifi-
cantly reduce the incidence of HZ as well as significantly
decrease the severity of neuropathic complications.35
Population studies are now needed to evaluate whether
immunization to prevent HZ could also reduce the
incidence of vascular events including stroke, TIA,
and MI. More research is needed to understand the
pathogenesis of increased HZ in patients with risk fac-
tors for vascular disease and to determine the impact of
treatment on risk. Notably, the role, if any, of asymp-
tomatic VZV reactivation in the pathogenesis of vascu-
lar disease and how this might be affected by zoster
immunization needs further clarification. In the mean-
time, the vaccine could now be offered to adults with
risk factors for vascular disease, irrespective of age, to
reduce the associated risk of HZ.4,31 At the same time,
screening for vascular risk factors in patients presenting
with HZ, especially younger patients in whom interven-
tion may have the most impact, should now be encour-
aged. Ultimately high-coverage childhood varicella
vaccination to reduce latency with wild-type virus is
altogether desirable.
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